ADEMPA contains Riociguat 2.5 mg, a soluble guanylate cyclase (sGC) stimulator used in the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). It improves exercise capacity and delays disease progression by enhancing the nitric oxide signaling pathway, leading to vasodilation of the pulmonary arteries.